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Identity 
Other names: KAIA302, KIAA1760, NY-CO-43, 
P/OKcl.13, PRKWNK2, SDCCAG43 
HGNC (Hugo): WNK2 
Location: 9q22.31 
Local order: The WNK2 gene is covered by BAC 
clones RP11-370F5, RP11-480F4 and RP11-165J3 and 




The human WNK2 gene is composed of 31 exons 
spanning 136 Kbp on chromosome 9q22.31. The 
promoter region contains a 700 bp CpG island between 
1103 bp and 396 bp upstream of the ATG translation 
start codon. A second CpG island spans exon 1 from 
135 bp upstream of the ATG translation start codon 
until 638 bp downstream of the ATG and close to the 
end of exon 1. 
Transcription 
Two major alternative transcripts exist depending on 
the terminal exon chosen.  
One variant uses exons 1-30, has a coding sequence of 
6894 bp and yields WNK2(1-2297) (related to clone 
KIAA1760, Acc. Nb. AB051547). The other variant 
skips exon 30 and includes exon 31, has a coding 
sequence of 6765 bp and yields WNK2(1-2254) 
(related to clone Kaia302; Acc. Nb. AK000694). Both 
terminal exons 30 and 31 carry their own 3'-
untranslated regions and polyadenylation signals. In 
addition, there is evidence for alternative splicing in 





Amino acids: 2297 or 2254. Molecular Weight: 243000 
Daltons. The WNK2 protein encodes a cytoplasmic 
serine-threonine kinase that lacks a lysine in subdomain 
II required for ATP-binding in most protein kinases and 
instead uses an alternative lysine in subdomain I. WNK 
kinase form a separate family branch, most closely 
related to kinases MEKK, Raf and PAK. 
 
Human WNK2 gene structure. The gene spans 136 Kbp, contains 31 exons and localizes to chromosome 9q22.31. Exons (vertical 
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Diagram of the WNK2 protein in scale. The sequence contains a catalytic domain near the N-terminus and a coiled coil domain near 
the C-terminus. Except for three short homology regions shared with the three other human WNK kinases, no other functional domains 
are known. The two splicing variants WNK2(1-2297) and WNK2(1-2254) differ in the C-terminal protein sequence. 
 
Expression 
WNK2 is preferentially expressed in heart, skeletal 
muscle and brain but also in small intestine, colon and 
liver. Loss of expression was reported in a large 
percentage of human gliomas (Hong et al., 2007) and 
grade II and III meningiomas (Jun et al., 2009) due to 
extensive methylation in the CpG island at the 5' end of 
the WNK2 gene. In contrast, promoter methylation was 
rare in other tumor types. This finding makes WNK2 a 
candidate tumor suppressor gene in brain tumors. 
Localisation 
The subcellular localization of GFP-tagged WNK2 in 
HeLa cells was predominantly cytoplasmic. Part of the 
endogenous WNK2 pool in HT29 colorectal cells 
localized to the plasma membrane and overexpression 
of a WNK2(1922-2156) that contains the coiled-coil 
domain was targeted to the plasma membrane. 
Function 
Human WNK2 modulates the activation level of ERK1 
and ERK2. Experimental depletion of WNK2 or 
overexpression of a kinase-dead WNK2K207M mutant 
led to increased phospho-ERK1/2 levels when a basal 
ERK stimulation was present but not, for example, in 
serum-free culture conditions (Moniz et al., 2007). This 
increase in ERK1/2 activation promoted cell cycle 
progression through G1/S and sensitized cells to 
respond to lower concentrations of EGF. From these 
data one might predict that loss of WNK2 expression 
will promote cell cycle progression in tumor cells.  
Interestingly, WNK2 expression is silenced in a 
significant percentage of human gliomas (Hong et al., 
2007) suggesting that this pathway may be used in 
some tumor types to promote cell proliferation. The 
molecular mechanism through which a reduction in 
WNK2 expression can increase ERK1/2 activation 
involves phosphorylation of MEK1 at serine 298, a 
modification that increases MEK1 affinity towards 
ERK1/2. Apparently, WNK2 affects PAK1 activation 
via Rac1 and PAK1 is the kinase responsible for MEK1 
S298 phosphorylation (Moniz et al., 2008). 
Homology 
The catalytic domain of WNK2 is 90% identical to 
WNK1, 91% identical to WNK3 and 81% identical to 
WNK4. The remaining sequence of WNK2 has little 
homology to other WNK members except for three 
small WNK homology regions (Holden et al., 2004; 
Moniz et al., 2007). These include an acidic motif 
(residues 586-597) to which hereditary mutations in 
WNK4 cluster (Wilson et al., 2001), residues 1186-
1261 without any recognizable motif, and residues 
1918-1988 including a coiled-coil domain. 
Mutations 
Note 
At present it is unclear whether the observed somatic 
mutations have a functional impact on the WNK2 
protein or confer any selective advantage to tumors 
cells. 
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Tissue Histology/Type cDNA Protein Mutation Ref 
Colorectal adenocarcinoma c.1964delC p.P655fs*2 
Frameshift 
deletion 
Greenman et al., 2007 
Brain glioblastoma c.3799G>A p.A1267T Missense Parsons et al., 2008 
Stomach adenocarcinoma c.4269delC p.S1424fs*5 
Frameshift 
deletion 




c.5009G>A p.G1670E Missense 
Greenman et al., 2007; Davies et 
al., 2005 
Lung adenocarcinoma c.6089G>T p.S2030I Missense 
Greenman et al., 2007; Davies et 
al., 2005 
Ovary serous carcinoma c.1528G>T p.V510L  Missense Greenman et al., 2007 
Ovary mucinous carcinoma c.6798delC p.T2267fs*31 
Frameshift 
deletion 
Greenman et al., 2007  
 
Germinal 
No germinal mutations described. 
Somatic 
Somatic mutations in WNK2 have been found in the 
course of large scale tumor genome sequencing efforts 
(see Table above). 
Heterozygous somatic mutations in the WNK2 gene 




Promoter methylation leads to loss of expression. 
Disease 





WNK2 clone was isolated as a serologically defined 
colon cancer antigen 43; WNK2 is expressed in colon. 
To be noted 
Possible role in invasion due to the effect of WNK2 on 
Rho-GTPases. WNK2 controls (through a yet unknown 
mechanism) the activation of RhoA, which in turn 
determines the activation of Rac1 in a reciprocal 
manner. Experimental depletion of WNK2 leads to 
reduced RhoA and increased Rac1 activation. 
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